Clinical Trial Update: Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating NVA237 for poorly controlled asthma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• NVA237

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 3 | Status: WITHDRAWN